Jeffrey G. Barlow, CFA, was appointed CEO of Canaccord Genuity LLC (US) in June 2023. Previously, he served as President, Canaccord Genuity LLC since October 2015 and in this capacity has engineered and overseen substantial growth in the Company’s US Investment Banking and Capital Markets operations. Jeff is a member of the Global Operating Committee of Canaccord Genuity Group Inc. He joined the firm in February 2007 and successfully expanded the firm’s Life Sciences practice before becoming Head of US Investment Banking in 2011. He has extensive experience advising clients across Life Sciences with an emphasis on Med Tech and Diagnostics and has completed hundreds of financings and M&A transactions.
Prior to joining Canaccord Genuity, Jeff was a Managing Director and the Head of Healthcare Investment Banking at First Albany Corporation, where he was responsible for establishing and building the firm’s healthcare practice. He began his career at J.P. Morgan.
Jeff earned the Chartered Financial Analyst (CFA) designation and is a frequent speaker on industry topics. He received his B.A. from the University of New Hampshire and MBA, with Beta Gamma Sigma distinction, from the Leonard N. Stern School of Business at New York University.
Selected Transactions
-
TransMedics
Financial Advisor (Buy side)
-
US$460m
Natera
Co-Manager (Follow-On Offering)
-
US$130m
TransMedics Group, Inc.
Lead Manager (Follow-On Offering)
-
Biorez, Inc.
Financial Advisor (Sell side)
-
N/a
OrthogenRx, Inc.
Financial Advisor (Sell side)
-
US$60m
obp Medical Corporation
Financial Advisor to obp Medical Corporation on sale of assets to CooperSurgical, Inc
-
US$69m
Exagen Inc.
Bookrunner (Follow-on)
-
US$250m
Quanterix Corporation
Lead Manager (CMPO)
-
US$75m
Neuronetics, Inc.
Lead Manager (Follow-on)